PRO95780 (Not yet branded)
Other Medications
Description
PRO95780 is an experimental therapeutic agent being developed for colorectal cancer treatment in combination regimens. Based on clinical trial data, it is being evaluated alongside standard chemotherapy backbones including FOLFOX with bevacizumab for treatment-naive patients with locally advanced disease, and with cetuximab plus irinotecan or FOLFIRI plus bevacizumab for previously treated patients. The compound appears designed to enhance the efficacy of established CRC treatment combinations across different lines of therapy.
Mechanism of Action
The specific molecular mechanism of action for PRO95780 has not been publicly disclosed in available clinical documentation. Given its use in combination with both anti-EGFR therapy (cetuximab) and anti-VEGF therapy (bevacizumab) across different treatment settings, it likely targets a complementary pathway involved in colorectal cancer progression or resistance mechanisms.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.